EnBiotix Overview
- Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
5
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.46M
EnBiotix General Information
Description
Operator of a bioengineering company specializing in the development of therapies for drug-resistant bacterial infections. The company develops drugs focused on therapies for cystic fibrosis, non-CF bronchiectasis, and non-tuberculosis mycobacterial infections, enabling patients to avail treatment for chronic, recurrent, and life-threatening pulmonary infections.
Contact Information
Formerly Known As
Anagenix Therapeutics
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 197 West Springfield Street
- Boston, MA 02118
- United States
+1 (508) 000-0000
EnBiotix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 05-Apr-2022 | $3.46M | 00.000 | Completed | Clinical Trials - General | |
| 6. Merger/Acquisition | 29-Dec-2021 | 000.00 | Completed | Clinical Trials - General | ||
| 5. Later Stage VC | 29-Dec-2021 | 0000 | 000.00 | Completed | Clinical Trials - General | |
| 4. Later Stage VC (Series B) | 26-Sep-2019 | 00.000 | 00.000 | 000.00 | Completed | Clinical Trials - General |
| 3. Grant | 26-May-2016 | 00000 | 000 | Completed | Clinical Trials - General | |
| 2. Later Stage VC (Series A) | 12-May-2016 | $2M | $2M | 000.00 | Completed | Clinical Trials - General |
| 1. Grant | 01-Jan-2016 | $264K | Completed | Startup |
EnBiotix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series C | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00 |
| Series A | 2,200,000 | $0.001000 | 5% | $1.32 | $1.32 | 1x | $1.32 | 12.97% |
EnBiotix Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Operator of a bioengineering company specializing in the development of therapies for drug-resistant bacterial infection
Drug Discovery
Boston, MA
5
As of 2021
00.000
0000000000 0
00.000
000 00
ua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut a
0000 000000000
Philadelphia, PA
00
As of 0000
00000
0000
0000-00-00
00000000000
00000
000000
t enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqui
0000 000000000
Aberdeen, United Kingdom
00
As of 0000
000.00
00000000000
000.00
Add Comparison
EnBiotix Competitors (77)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | 00 | 00000 | 00000000000 | 00000 |
| 00000000000 | Venture Capital-Backed | Aberdeen, United Kingdom | 00 | 000.00 | 00000000000 | 000.00 |
| 000000 000 | Formerly VC-backed | Menlo Park, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 000000 | Formerly VC-backed | Lyon, France | 000 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
EnBiotix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EnBiotix Patents
EnBiotix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3983009-A1 | Antibiotic potentiation for nontuberculous mycobacterial disease | Pending | 13-Jun-2019 | 0000000000 | |
| JP-2022536368-A | Boosting antibiotics for nontuberculous mycobacterial diseases | Pending | 13-Jun-2019 | 000000000 | |
| US-20220233523-A1 | Antibiotic potentiation for nontuberculous mycobacterial disease | Pending | 13-Jun-2019 | 0000000000 | |
| EP-3551191-A1 | Aminoglycoside potentiation for treatment of pulmonary bacterial infection | Pending | 09-Dec-2016 | 00000000000 | |
| CA-3046085-A1 | Aminoglycoside potentiation for treatment of pulmonary bacterial infection | Pending | 09-Dec-2016 | A61K31/7036 |
EnBiotix Executive Team (5)
EnBiotix Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bernard Bollag | Spexis | Board Member | 000 0000 |
| Dan Hartman MD | EnBiotix | Board Member | 000 0000 |
| Dennis Ausiello Ph.D | Self | Board Member | 000 0000 |
| Jeffrey Wager MD | Self | Co-Founder, Chairman, President & Chief Executive Officer | 000 0000 |
| Kuno Sommer Ph.D | Spexis | Board Member | 000 0000 |
EnBiotix Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
EnBiotix Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Apeiron Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Bill & Melinda Gates Foundation | Not-For-Profit Venture Capital | 000 0000 | 000000 0 | ||
| Cystic Fibrosis Foundation | Limited Partner | 000 0000 | 000000 0 | ||
| Sanford Biosciences | Corporation | 000 0000 | 000000 0 | ||
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |
EnBiotix Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000 000000000 | 03-Nov-2016 | 0000000000 | Drug Discovery | 0000000 0 |